ESRD Clinical Trial
Official title:
Safety and Efficacy of Canagliflozin in Advanced CKD
The study objective is to characterize the pharmacokinetics (PK), pharmacodynamics, and surrogate measures of efficacy for canagliflozin in patients with advanced CKD, including those receiving HD. As the CV and renoprotective effects of SGLT-2 inhibitors appear to be independent of glycemic control, the investigators hypothesize that canagliflozin will reduce albuminuria in patients with advanced CKD in the same manner as observed in patients with higher eGFR. The investigators also hypothesize that the 300 mg dose will be equally safe as the 100 mg dose but will have greater efficacy, given data which suggests efficacy correlates with drug exposure in patients without CKD. Given its negligible renal elimination, the investigators hypothesize that exposure to canagliflozin 100 mg at steady state will not exceed the standard bioequivalence boundary of 80-125% in patients receiving HD, compared with published estimates with the 300 mg dose at steady state in individuals with preserved kidney function.
Substudy 1: Patients with eGFR<30 ml/min/1.73m2 and urine albumin to creatinine ratio (UACR)>200 mg/g not receiving dialysis will receive canagliflozin 100 mg po daily for 12 weeks (phase 1). For participants who have tolerated the drug, canagliflozin will be increased to 300 mg po daily for an additional 12 weeks (phase 2) and then stopped. Each phase will be followed by a 2-week window to ascertain surrogate efficacy outcomes. Substudy 2: Adult patients on HD for at least 3 months without significant residual renal function will receive canagliflozin 100 mg po daily for 9 days. ;
| Status | Clinical Trial | Phase | |
|---|---|---|---|
| Completed |
NCT03246984 -
VALUE- Vascular Access Laminate eUropean Experience. A Post Market Surveillance Study to Assess the Safety and Effectiveness of VasQ
|
N/A | |
| Completed |
NCT03943212 -
The Effect of Blood Flow Rate on Dialysis Recovery Time in Patients Undergoing Maintenance Hemodialysis
|
N/A | |
| Completed |
NCT03456648 -
Apixaban in End-stage Kidney Disease : A Pharmacokinetics Study
|
Phase 2 | |
| Completed |
NCT00966615 -
The Effect of Neutral Peritoneal Dialysis (PD) Solution With Minimal Glucose-Degradation-Product (GDP) on Fluid Status and Body Composition
|
Phase 4 | |
| Completed |
NCT01252771 -
Phosphate Kinetic Modeling 2
|
Phase 4 | |
| Completed |
NCT00850252 -
Use of a Lifeline Graft in the A-V Shunt Model
|
Phase 1/Phase 2 | |
| Completed |
NCT00294502 -
Antibiotic Lock Solutions in the Prevention of Catheter Related Bacteremia
|
Phase 4 | |
| Completed |
NCT05011136 -
Physician Reimbursement Home Patients
|
||
| Completed |
NCT05144971 -
StatStrip A Glucose/Creatinine Meter System Lay User Study Evaluation
|
||
| Completed |
NCT02278562 -
Nutrition, Inflammation and Insulin Resistance in End Stage Renal Disease-Aim 2
|
Phase 2 | |
| Completed |
NCT01424787 -
Non-interventional Study to Evaluate the Ease of Reaching Individual Goals in Serum Phosphorus (Steering)
|
N/A | |
| Terminated |
NCT00580762 -
Bariatric Surgery for ESRD Patients vs Control
|
N/A | |
| Recruiting |
NCT05339139 -
SAfety of Regional Citrate Anticoagulation (SARCA Study)
|
Phase 3 | |
| Completed |
NCT03242343 -
VasQ External Support for Arteriovenous Fistula
|
N/A | |
| Completed |
NCT02966028 -
Effect of SNF472 on Progression of Cardiovascular Calcification in End-Stage-Renal-Disease (ESRD) Patients on Hemodialysis (HD)
|
Phase 2 | |
| Not yet recruiting |
NCT02596386 -
Examination of Potassium Levels in Saliva in ESRD Patients
|
N/A | |
| Completed |
NCT02513303 -
Trial to Evaluate the Sirolimus-Eluting Collagen Implant on AV Fistula Outcomes
|
Phase 3 | |
| Active, not recruiting |
NCT02270515 -
Bringing Care to Patients: Patient-Centered Medical Home for Kidney Disease
|
N/A | |
| Recruiting |
NCT06001827 -
SAVE-FistulaS: the SelfWrap-Assisted ArterioVEnous Fistulas Study
|
N/A | |
| Terminated |
NCT03303391 -
Using Intradialytic Blood Pressure Slopes to Guide Ultrafiltration
|
N/A |